Sheehan disability scale as outcome measure in depressed out-patients

详细信息	查看全文 | 推荐本文 |

• 作者：E. Erkens ; K. Jonker ; M. Blom ; J. Haffmans ; E. Hoencamp*
• 关键词：Photovoltaics ; Incentive programs ; Performance
• 刊名：Journal of Affective Disorders
• 出版年：2008
• 期刊代码：141_01650327
• 类别：med
• 出版时间：March 2008
• 卷：107
• 期：Supplement 1
• 页码：S103
• 文件大小：52 K

摘要

Method: Patients (n = 243) with panic disorder were randomized to fluoxetine or placebo treatment. Primary outcome measures were change in total panic attack frequency and CGI-Improvement. Other assessments included clinician and patient-rated panic and phobic disorder change, phobia rating scale, HAMA, HAMD-21, and Sheehan Disability scale. Correlations between outcomes in individual symptom domains and overall clinical outcome were determined, as were patterns of response.

Results: Total panic attack reduction and CGI-improvement was significantly greater in fluoxetine-treated compared with placebo-treated patients (p = .015 and p = .040, respectively). Fluoxetine was also superior to placebo in reducing illness-associated anxiety (p = .004), depression (p = .008), phobic symptoms (p = .002), and improved functional outcomes, as assessed by the Sheehan Disability Scale (p = .025). Global improvement correlated most highly with reductions in overall anxiety and phobic symptoms, and least with reduction in panic attacks. Among patients with a CGI-Improvement score of 1 or 2 at Visit 8, fluoxetine 20 mg was associated with statistically significantly greater reduction in panic attacks compared with placebo.

Conclusions: These data support the efficacy and safety of fluoxetine treatment in reducing panic attacks and associated symptoms in patients with panic disorder. Reductions in panic attack frequency were less closely related to overall clinical improvement than other symptom domains.